An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705
← catalyst calendarNCT05295433 · readout in 2,783 d
Sponsored by ModernaTX, Inc. (industry) · MRNA — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
56estimated
Sites
12
Countries
Canada, France, Netherlands +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-03-08 | actual | When the study began enrolling |
| Primary completion | 2034-04-02 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2034-04-02 | estimated | The whole study's end, after follow-up |
| First posted | 2022-03-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Methylmalonic Acidemia
Intervention
- Drug: mRNA-3705 — also filed as modified mRNA encoding human, methylmalonyl-coenzyme A mutase
Primary outcome
what the primary-completion date above is the date OFNumber of Participants With Treatment-Emergent Adverse Events (TEAEs), Drug-Related TEAEs, Unrelated TEAEs, Adverse Events of Special Interests (AESIs), Serious Adverse Events (SAEs) and TEAEs Leading to Discontinuation
measured Baseline up to follow-up period (up to 6 years + 6 months)
Permalink · MRNA's whole pipeline · Catalyst calendar · Every registered study · What changed